Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Apollomics Inc. Class A Ordinary Shares (APLM)

https://www.apollomicsinc.com

Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/30/2023

Market Cap

14,604,233

Shares Outstanding

89,480,000

Weighted SO

89,480,790

Total Employees

N/A

Upcoming Earnings

04/28/2023

Similar Tickers

Beta

1.2210

Last Div

0.0000

Range

0.125-5.19

Chg

-0.0136

Avg Vol

3912941

Mkt Cap

14604233

Exch

NASDAQ

Country

US

Phone

650 209 4055

DCF Diff

-0.2113

DCF

0.3682

Div Yield

0.0000

P/S

17.7883

EV Multiple

0.2393

P/FV

0.2895

Div Yield %

0.0000

P/E

-0.0692

PEG

-0.0028

Payout

0.0000

Current Ratio

2.9452

Quick Ratio

3.4040

Cash Ratio

2.3647

DSO

207.1742

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

1.0000

Op Margin

-65.2241

Pretax Margin

-210.2205

Net Margin

-210.2326

Eff Tax Rate

-0.0001

ROA

-3.1163

ROE

-3.5613

ROCE

-1.2801

NI/EBT

1.0001

EBT/EBIT

3.2230

EBIT/Rev

-65.2241

Debt Ratio

0.0842

D/E

0.1130

LT Debt/Cap

0.0064

Total Debt/Cap

0.1016

Int Coverage

0.0000

CF/Debt

-9.2703

Equity Multi

1.3432

Rec Turnover

1.7618

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

1.4010

Asset Turnover

0.0148

OCF/Share

-0.4864

FCF/Share

-0.4865

Cash/Share

0.4257

OCF/Sales

-52.6297

FCF/OCF

1.0001

CF Coverage

-9.2703

ST Coverage

-9.8336

CapEx Coverage

-7201.5000

Div&CapEx Cov

-7201.5000

P/BV

0.2895

P/B

0.2895

P/S

17.7883

P/E

-0.0692

P/FCF

-0.3379

P/OCF

-0.2763

P/CF

-0.2763

PEG

-0.0028

P/S

17.7883

EV Multiple

0.2393

P/FV

0.2895

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 19, 16:15 Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency GlobeNewswire Inc. Jan 17, 16:30 Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference GlobeNewswire Inc. Jan 02, 16:30 Apollomics to Present at the 2024 Biotech Showcase GlobeNewswire Inc. Nov 29, 07:30 Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference Benzinga Nov 27, 13:41 Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session GlobeNewswire Inc. Oct 31, 08:30 Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation GlobeNewswire Inc. Oct 26, 08:50 Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Revenue Product Segmentation